Clinical Trial Update: CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating CapeOX plus Bevacizumab and an anti-PD-1 antibody for locally recurrent colorectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anti-PD-1 antibody
• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Locally Recurrent Colorectal Cancer | Phase 2 | Status: RECRUITING